Vaccines

Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously

Retrieved on: 
Monday, June 14, 2021
Medical specialties, Vaccination, Drugs, Clinical trials, COVID-19 vaccines, Influenza vaccine, Vaccines, Vaccine efficacy, Vaccine, Novavax COVID-19 vaccine, Novavax, COVID-19 vaccine

In addition, the protection afforded by the candidate vaccine was consistent with the main study at 87.5% and 89.8% respectively.

Key Points: 
  • In addition, the protection afforded by the candidate vaccine was consistent with the main study at 87.5% and 89.8% respectively.
  • All received an approved seasonal influenza vaccine with approximately half the participants co-vaccinated with NVX-CoV2373 while the remainder received placebo.
  • The study demonstrated that vaccine efficacy appeared to be preserved in those receiving both vaccines compared to those vaccinated with NVX-CoV2373 alone.
  • Furthermore, immunogenicity of the influenza vaccine was preserved with concomitant administration while a modest decrease in the immunogenicity of the NVX-CoV2373 vaccine was found.

Moderna Submits Authorization Application for its COVID-19 Vaccine in Adolescents in Switzerland

Retrieved on: 
Monday, June 14, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Medical Supplies, COVID-19, COVID-19 vaccines, Clinical trials, Medicine, Vaccines, Medical research, RNA vaccines, Moderna COVID-19 vaccine, COVID-19 vaccine, Vaccine, Moderna, COVID-19 vaccination in Switzerland, the Moderna COVID-19 Vaccine, Moderna, THE MODERNA COVID-19 VACCINE, MODERNA

We are pleased to announce that we have submitted an authorization application for our COVID-19 vaccine with Swissmedic for use in adolescents in Switzerland, said Stphane Bancel, Chief Executive Officer of Moderna.

Key Points: 
  • We are pleased to announce that we have submitted an authorization application for our COVID-19 vaccine with Swissmedic for use in adolescents in Switzerland, said Stphane Bancel, Chief Executive Officer of Moderna.
  • We are encouraged that the Moderna COVID-19 vaccine was highly effective at preventing COVID-19 and SARS-CoV-2 infection in adolescents.
  • In the study, no cases of COVID-19 were observed in participants who had received two doses of the Moderna COVID-19 vaccine using the primary definition.
  • The vaccine efficacy in the nearly 2,500 adolescents who received the Moderna COVID-19 vaccine was observed to be 100% when using the same case definition as in the Phase 3 COVE study in adults.

Global WholeHealth Partners Corp. (GWHP-OTC) Acquires Rights to Distribute & Sell Johnson & Johnson COVID-19 Vaccine

Retrieved on: 
Monday, June 14, 2021
COVID-19 vaccines, Clinical trials, Vaccines, Health sciences, Medicine, Medical research, Adenoviridae, RNA vaccines, Johnson & Johnson COVID-19 vaccine, Johnson & Johnson, COVID-19 vaccine

The Company has recently filed an 8K stating that: Effective June 9, 2021, Global WholeHealth Partners Corporation (the Company) was granted the rights from Nunzia Pharmaceutical Inc. (Nunzia) to distribute and sell the Johnson & Johnson COVID-19 Vaccine (Vaccine).

Key Points: 
  • The Company has recently filed an 8K stating that: Effective June 9, 2021, Global WholeHealth Partners Corporation (the Company) was granted the rights from Nunzia Pharmaceutical Inc. (Nunzia) to distribute and sell the Johnson & Johnson COVID-19 Vaccine (Vaccine).
  • As of April 20, 2021, Johnson & Johnsons Covid-19 vaccine contributed $100 million to J&Js sales growth in the latest quarter.
  • [1] J&J said its pharmaceutical business, which developed the single-shot Covid-19 vaccine, generated $12.19 billion in revenue, a 9.6% year-over-year increase.
  • Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov .

COVID-19 Vaccine Drug Substance Manufactured by Emergent BioSolutions Authorized as Part of Johnson & Johnson’s Emergency Use Authorization

Retrieved on: 
Friday, June 11, 2021
COVID-19 vaccines, Clinical trials, Vaccines, Health sciences, Health, RNA vaccines, Adenoviridae, Janssen Pharmaceutica, Johnson & Johnson COVID-19 vaccine, Johnson & Johnson, Pfizer–BioNTech COVID-19 vaccine, COVID-19 vaccine

We are pleased that these initial doses of the Johnson & Johnson COVID-19 vaccine will be available to protect millions of people from this deadly disease, said Robert G. Kramer, president and chief executive officer of Emergent.

Key Points: 
  • We are pleased that these initial doses of the Johnson & Johnson COVID-19 vaccine will be available to protect millions of people from this deadly disease, said Robert G. Kramer, president and chief executive officer of Emergent.
  • We look forward to working with the FDA and Johnson & Johnson toward the release of additional batches and resuming production at our Bayview facility.
  • Emergent is actively addressing issues identified by the FDA at its Bayview facility and plans to resume manufacturing of the Johnson & Johnson COVID-19 vaccine drug substance after Emergent, Johnson & Johnson, and FDA are confident that the steps taken have remedied shortcomings.
  • Since mid-2020, Emergent has harnessed its capabilities to rapidly build and scale up capacity to manufacture bulk drug substance for Johnson & Johnsons COVID-19 vaccine.

Bavarian Nordic Assists Public Health England in Response to New Cases of Monkeypox

Retrieved on: 
Friday, June 11, 2021
Medical specialties, Clinical medicine, Medicine, Bavarian Nordic, Vaccines, Chordopoxvirinae, Monkeypox, Smallpox vaccine, Vaccine, Smallpox

COPENHAGEN, Denmark, June 11, 2021 Bavarian Nordic A/S (OMX: BAVA) announced today that the Company was recently engaged by Public Health England (PHE) and the Medicines and Health Products Regulatory Agency (MHRA) to supply its IMVANEX smallpox vaccine in response to new cases of monkeypox in the UK.

Key Points: 
  • COPENHAGEN, Denmark, June 11, 2021 Bavarian Nordic A/S (OMX: BAVA) announced today that the Company was recently engaged by Public Health England (PHE) and the Medicines and Health Products Regulatory Agency (MHRA) to supply its IMVANEX smallpox vaccine in response to new cases of monkeypox in the UK.
  • Monkeypox is a rare, but serious disease, which is endemic in Central and West Africa.
  • Paul Chaplin, President and CEO of Bavarian Nordic said: We are pleased to assist Public Health England rapidly in such an emergency situation.
  • Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacture and commercialization of life-saving vaccines.

Thinking about buying stock in Vaxart, Graybug Vision, Jaguar Health, iBio, or Aptinyx?

Retrieved on: 
Friday, June 11, 2021
Life sciences, Biotechnology, Medical research, Vaccines, Vaxart, Health sciences, Stock market

InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology.

Key Points: 
  • InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology.
  • Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
  • Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
  • View original content to download multimedia: http://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-v...

MigVax’s Subunit Oral COVID-19 Vaccine Preclinical Trial Demonstrates Effectivity as a Booster

Retrieved on: 
Thursday, June 10, 2021
Professional services, Health, Infectious diseases, Finance, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Medicine, COVID-19 vaccines, Virology, Health sciences, Clinical trials, Medical research, Vaccines, Vaccine, COVID-19 vaccine, Herpes simplex research

MigVax Ltd., a startup company developing an oral subunit vaccine against COVID-19, today announced promising results from preclinical tests that demonstrated the effectivity of its MigVax-101 subunit oral vaccine as a booster for previously vaccinated persons.

Key Points: 
  • MigVax Ltd., a startup company developing an oral subunit vaccine against COVID-19, today announced promising results from preclinical tests that demonstrated the effectivity of its MigVax-101 subunit oral vaccine as a booster for previously vaccinated persons.
  • In the trial, tests carried out on rats demonstrated that the MigVax-101 sub-unit oral vaccine, when administered in a boost format following an injected S1 protein, elicited markedly higher neutralizing antibody titers than rats receiving an oral placebo booster.
  • As an oral vaccine, Mig-Vax-101 offers significant potential advantages over todays first- generation injected vaccines:
    Ease of administration: Oral administration obviates the need for administration by healthcare professionals.
  • MigVax is using the methods learned from the existing vaccine to develop a new oral subunit human vaccine against COVID-19.

North America Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 10, 2021
Health, Pharmaceutical, Medicine, Medical specialties, Health, Virology, Vaccines, Medical research, Vaccination, Vaccine, COVID-19 vaccine, Vaccine hesitancy, Influenza vaccine

The "North America Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.
  • North America preventive vaccines market is expected to grow by 10.42% annually in the forecast period and reach $30.02 billion by 2026 owing to increasing healthcare expenditure, new development of the vaccines, and rising need for preventive vaccines especially new COVID-19 vaccines.
  • Highlighted with 51 tables and 48 figures, this 131-page report "North America Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity" is based on a holistic research of the entire North America preventive vaccines market and all its sub-segments through extensively detailed classifications.
  • The report is based on studies on 2016-2019 and provides estimate/forecast from 2020 till 2026 with 2019 as the base year.

 Significant and Sustained Drop in Teen and Adult Immunization Rates During Pandemic, Study Shows

Retrieved on: 
Wednesday, June 9, 2021
Drugs, Medicine, Medical specialties, Vaccines, Vaccination, Vaccine, Virology, Influenza vaccine, Medical research, Clinical trials, Gavi, COVID-19 vaccination in Canada

Teens and adults potentially missed over 26 million doses of recommended vaccines in 2020.This includes 8.8 million missed adolescent vaccine doses and 17.2 million missed adult vaccine doses.

Key Points: 
  • Teens and adults potentially missed over 26 million doses of recommended vaccines in 2020.This includes 8.8 million missed adolescent vaccine doses and 17.2 million missed adult vaccine doses.
  • Vaccine claims remain well below 2019 levels.Total non-influenza vaccine claims submissions were between 13-35% (adolescents) and 17-40% (adults) lower than the same period in 2019.
  • Despite warnings of a potential "twindemic," influenza immunization rates were lower in 2020 than in 2019.
  • GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

VBI Vaccines Announces Multiple Abstracts Accepted for Poster Presentations at EASL 2021

Retrieved on: 
Wednesday, June 9, 2021
Research, Infectious diseases, FDA, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Medical specialties, Clinical medicine, Health, Infectious causes of cancer, Hepatitis B, Vaccines, Hepatitis, Hepatocellular carcinoma, Cirrhosis, Variation Biotechnologies, Hepatitis B, VBI-2601 (BRII-179), VBI’s 3-Antigen Hepatitis B Vaccine, VBI Vaccines Inc., HEPATITIS B, VBI-2601 (BRII-179), VBI’S 3-ANTIGEN HEPATITIS B VACCINE, VBI VACCINES INC.

An estimated 900,000 people die each year from complications of chronic HBV such as liver decompensation, cirrhosis, and hepatocellular carcinoma.

Key Points: 
  • An estimated 900,000 people die each year from complications of chronic HBV such as liver decompensation, cirrhosis, and hepatocellular carcinoma.
  • To learn more about VBIs 3-Antigen Hepatitis B vaccine candidate visit: https://www.vbivaccines.com/sci-b-vac/
    VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease.
  • VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM).
  • VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.